Compare Aptiv PLC (APTV) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Danaher Corporation — how do they compare? Aptiv PLC trades at $50.1 (market cap $10.34B), while Danaher Corporation trades at $207.4 (market cap $147.18B). The key difference: Danaher Corporation is far larger — about 14.2× Aptiv PLC's market cap, and Danaher Corporation pays a 0.76% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | DHR | |
|---|---|---|
Market Cap | $10.34B | $147.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $242.05 |
52-Week Low | $46.30 | $161.91 |
Enterprise Value | $15.27B | $169.39B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV stock trades at $49.55, up 7.02% in the last session, but remains under bearish technical pressure with support at $48 and resistance at $50. The company reported Q2 2026 EPS of $1.63, beating estimates, but lowered full-year guidance due to weak China demand. Revenue grew 2% year-over-year to $20.4B in 2025, though net margins compressed to 1.07%.
The outlook is mixed: strong analyst buy consensus (63.6%) and a $70.09 price target suggest upside, but technical weakness, margin pressures, and China exposure pose near-term risks. Earnings beats highlight operational strength, but investors face volatility from guidance cuts and competitive headwinds.
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
